Schwarz Pharma AG
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Schwarz Pharma AG
UCB Links With Daiichi Sankyo For Epilepsy In Japan
UCB has chosen Daiichi Sankyo as its new commercial partner in Japan for an epilepsy drug, building on an existing relationship in the allergy area.
UAE Drug Regulator Orders Recall Of Schwarz Pharma Heart Drug
The United Arab Emirates ordered a recall of Germany-based Schwarz Pharma's Nitrocine (glyceryl trinitrate) for treating heart and blood-pressure problems on grounds it may contain impurities.
Watson/Actavis Merger Requires Near Record Divestiture; Sandoz, Par Pick Up 18 Products
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
CEO Interview: AstraZeneca's David Brennan
David Brennan has sharpened AstraZeneca's therapeutic area focus and embraced external R&D. The next two years will determine whether the productivity drive is working--or if more radical change is needed.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice